STATUS Study Complete

Study of HBV Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B

Gilead Clinical Study Information Center:
Monday – Friday, 5am – 6pm PT
Email: [email protected]

STATUS

Study Complete

GILEAD STUDY ID

GS-US-642-5670

Gilead Clinical Study Information Center:
Monday – Friday, 5am – 6pm PT
Email: [email protected]

LAST UPDATED

January 23, 2026

Clinicaltrials.gov ID

NCT05770895

STUDY DOCUMENTS

View study documents

OVERVIEW

A Phase 1a/1b Study to Evaluate the Safety and Tolerability of Repeated Doses of Nonreplicating Arenavirus Vector Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B (CHB)

PROTOCOL SUMMARY

The goal of this clinical study is to learn more about GS-2829 and GS-6779 in healthy participants and participants with CHB.

Participation requirements

Age

18 years - 65 years

Sex

All

Healthy Volunteers

true

Study details

Medical Condition

Chronic Hepatitis B

Gender

N/A

Date

April 2023 - January 2025

Study Type

Interventional

Study Phase

Phase 1

Product

GS-2829, GS-6779, Placebo

Eligibility information

Inclusion criteria

Phase 1a and 1b:
Body mass index (BMI) of ≤ 32.0 kg/m^2.
Non-diabetic without impaired glucose tolerance.
No evidence of cardiac disease based on 12 lead electrocardiogram (ECG).
Phase 1a (Healthy Individuals) only:
Aged 18 through 60 years.
No prior history of Hepatitis B infection with a negative hepatitis B surface antigen (HBsAg) and Hepatitis B (HBV) core antibody.
Phase 1b (Virally Suppressed chronic hepatitis B (CHB) Individuals)):
Aged 18 through 65 years.
Documented CHB and HBsAg ≤ 5000 IU/mL at screening.
No evidence of advanced fibrosis by Fibroscan (defined as Fibroscan < 9 kilo pascal (kPa) within 6 months of screening).
Diagnosed with CHB on suppressive oral antiviral for ≥ 6 months.
Must have received an approved HBV-active oral antiviral agent for ≥ 6 months prior to screening with HBV DNA below lower limit of quantification (LLOQ) for ≥ 3 months prior to screening and with no plan to stop HBV-active antivirals during the study.

Exclusion criteria

Phase 1a and 1b:
Use of any systemic antibiotics within 30 days of screening.
Receipt of any HBV vaccine within 12 months of screening visit or planning HBV vaccination during the study period.
Receipt of any investigational product within 3 months or vaccine within 3 months of screening (with the exception of influenza and severe acute respiratory syndrome (SARs) coronavirus (COV) - 2 (SARS-CoV-2) vaccines, which if needed, should be administered at least 14 days before or after an investigational product administration).
Receipt of immunoglobulin or other blood products within 3 months of screening.
Positive serum pregnancy test at screening or positive urine pregnancy on Day 1.
Have been treated with systemic steroids, immunosuppressant therapies, or chemotherapeutic agents within 3 months prior to screening or is expected to receive these agents during the study (eg, corticosteroids, immunoglobulins, other immune or cytokine-based therapies).
Participation in any other clinical study (including observational studies) without prior approval from the sponsor is prohibited while participating in the study.
Note - Other protocol defined Inclusion/Exclusion criteria may apply.